Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors

Nicole Onetto, M.D., medical oncologist with strong track record in the development of targeted therapies in oncology joins NBE-Therapeutics' Board of Directors as independent Board member

Read more

Basel, 2017-05-15 - NBE-Therapeutics' publishes paper showcasing high potency of NBE's ADCs

Peer-reviewed paper describing NBE-Therapeutics' highly potent ADCs published in AACR journal Molecular Cancer Therapeutics

Read more

Basel, 2017-04-04 - NBE-Therapeutics expands Board by Appointment of Hans-Peter Gerber

Hans-Peter Gerber, internationally renowned expert in ADC development and previously CSO of Pfizer's Bioconjugates Division joins the Board of Directors of NBE-Therapeutics

Read more

Basel, 2016-11-03 - NBE-Therapeutics raises CHF 20 million in Series B financing

NBE-Therapeutics announces closing of a CHF 20 Mio series B financing round led by PPF Group and existing investors of NBE

Read more

next >